This issue brief provides background on the GENEROUS model, examines the factors that will contribute to the model’s overall impact on Medicaid drug costs, and illustrates how savings will depend on model details that are confidential or uncertain at this time.
Just a year after its launch, Bluebird Kids Health is already announcing plans to double its number of pediatric clinics. The startup seeks to improve pediatric care access in underserved areas by building practices in these neighborhoods and accepting all insurance types. The post Bluebird Kids Health to Expand By Opening New Pediatric Clinics appeared…
Trends in ICHRA adoption, product innovation, and regulatory developments signal that this benefits model isn’t just here to stay — it’s poised to help redefine how we think about employer-sponsored healthcare. The post 2025 Outlook: Significant Investments in ICHRA Signal Changes Ahead appeared first on MedCity News.
Johnson & Johnson is acquiring Halda Therapeutics for its lead program, a drug that recently posted encouraging Phase 1 data in advanced prostate cancer. This drug comes from a proprietary Halda platform technology that yields oral small molecules offering a novel mechanism for killing cancer cells. The post J&J’s $3B Halda Acquisition Brings a Way…
Crescent Biopharma is going public via a reverse merger with GlycoMimetics that will capitalize the combined company with $200 million. Crescent’s lead program is a bispecific antibody for cancer that replicates the properties of a Summit Therapeutics bispecific drug that recently trounced Merck’s blockbuster med Keytruda in a pivotal head-to-head study. The post Going In…
Sheldon Ekirch is used to being disappointed by her health insurance company. That’s why Ekirch, 31, of Henrico, Virginia, was stunned when she learned Anthem would finally have to pay for life-changing medical treatment. For two years, she had battled the company to cover blood plasma infusions called intravenous immunoglobulin, or IVIG. The treatment has…
A paper by Qato et al. (2024) quantifies the degree of of pharmacy benefit manager (PBM) market concentration. Across all payer types, the PBM market was highly concentrated, with an HHI [Herfindahl Hirschman Index (HHI)] of 1972…the HHI was lowest in commercial insurance (1940), with 90 PBM participants, and highest in Medicare Part D (2399),…
[Sponsored] Meevo offers an all-in-one solution for managing salon and spa employees. From scheduling and time tracking to payroll and promotions, Meevo streamlines operations and supports growth. The post Simplify Salon & Spa Employee Management with Meevo’s Comprehensive Software appeared first on MedCity News.
CMS’s Office of the Actuary predicts that national healthcare expenditures (NHE) will increase from 17.6% of GDP in 2023 to 20.3% of GDP by 2033. The Keehan et al. (2025) paper provides more details: National health expenditures are projected to have grown 8.2 percent in 2024 and to increase 7.1 percent in 2025, reflecting continued…
With the Trump administration scaling back federal efforts to protect Americans from medical bills they can’t pay, advocates for patients and consumers have shifted their work to contain the nation’s medical debt problem to state Capitols. Despite progress in some mostly blue states this year, however, recent setbacks in more conservative legislatures underscore the persistent…